Last Patient Dosed in Phase 3 Trials of Pulmaquin for Non-Cystic Fibrosis Bronchiectasis

News

Aradigm reported that the final patient has completed the last dose appointment in the ORBIT-3 and ORBIT-4 Phase 3 clinical trials assessing Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE) in ... Read more

November 24, 2015December 1, 2015

Aradigm’s Bronchiectasis Therapy Advancing in Phase 3 Studies

News

Aradigm Corporation, a pharmaceutical company dedicated to the prevention and treatment of severe pulmonary diseases, recently gave an update on its promising therapy Pulmaquin, now in fully enrolled clinical studies, and announced the ... Read more